- Home
- GAU vs ACRS Comparison
GAU vs ACRS Comparison
Compare GAU & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | ACRS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.6M | 529.9M |
| IPO Year | 2006 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GAU | ACRS |
|---|---|---|
| Price | $2.47 | $3.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $3.85 | ★ $10.36 |
| AVG Volume (30 Days) | 2.3M | ★ 3.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $99.00 | N/A |
| Revenue Next Year | $39.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $2.10 |
| 52 Week High | $3.62 | $6.60 |
Technical Indicators
Market Signals| Indicator | GAU | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 46.40 |
| Support Level | $2.40 | $3.18 |
| Resistance Level | $2.75 | $4.67 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 99.10 | 72.03 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.